RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

被引：0
|
作者：
Chunyue Wang
Zhenlong Zhang
Yulan Sun
Song Wang
Mengmeng Wu
Qiuxiang Ou
Yang Xu
Zhiming Chen
Yang Shao
Hong Liu
Peifeng Hou
机构：
[1] Xiamen University,Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine
[2] Shengli Clinical Medical College of Fujian Medical University,Department of Thoracic Surgery
[3] Fujian Provincial Hospital,Department of Internal Medicine Division
[4] Shandong Cancer Hospital Affiliated to Shandong First Medical University,Department of Radiation Oncology
[5] Geneseeq Research Institute,Department of Medical Oncology
[6] Nanjing Geneseeq Technology Inc.,undefined
[7] Affiliated Hospital of Nantong University,undefined
[8] Qilu Hospital of Shandong University,undefined
[9] Fujian Medical University Union Hospital,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
rearrangement; NSCLC; EGFR-TKI; Noncanonical ; fusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
    Wang, Chunyue
    Zhang, Zhenlong
    Sun, Yulan
    Wang, Song
    Wu, Mengmeng
    Ou, Qiuxiang
    Xu, Yang
    Chen, Zhiming
    Shao, Yang
    Liu, Hong
    Hou, Peifeng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [2] RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers
    Wang, C.
    Zhang, Z.
    Wu, M.
    Yin, J.
    Wu, X.
    Shao, Y.
    Hou, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S489 - S490
  • [3] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Gower, Arjan
    Wang, Yisong
    Giaccone, Giuseppe
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
  • [4] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower
    Yisong Wang
    Giuseppe Giaccone
    Journal of Molecular Medicine, 2014, 92 : 697 - 707
  • [5] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [6] Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
    Lin, J. J.
    Liu, S., V
    McCoach, C. E.
    Zhu, V. W.
    Tan, A. C.
    Yoda, S.
    Peterson, J.
    Do, A.
    Prutisto-Chang, K.
    Dagogo-Jack, I
    Sequist, L., V
    Wirth, L. J.
    Lennerz, J. K.
    Hata, A. N.
    Mino-Kenudson, M.
    Nardi, V
    Ou, S-H, I
    Tan, D. S-W
    Gainor, J. F.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1725 - 1733
  • [7] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [8] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [9] Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
    Tan, L.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1599 - 1600
  • [10] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    ONCOGENE, 2009, 28 : S24 - S31
12345